DM 101
Alternative Names: AllergyVax; Be-v-1-dm; Bet v 1 dm; DM 101PX; DM-101; rBet-v-1-dmLatest Information Update: 15 Apr 2025
At a glance
- Originator Desentum; University of Eastern Finland; VTT Technical Research Centre of Finland
- Developer Desentum
- Class Allergens; Tree pollen allergy immunotherapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Tree pollen hypersensitivity
Most Recent Events
- 02 Apr 2025 Adverse events and immunogenicity data from a phase-I trial in Tree pollen hypersensitivity released by Desentum
- 02 Apr 2025 Desentum plans a phase-II trial for Tree pollen hypersensitivity (SC),
- 06 Mar 2024 Desentum completes a phase I trial in Tree pollen hypersensitivity in Canada (SC) (NCT06037148)